Thoracic medical oncologist, Perlmutter Cancer Center NYU Langone Health. Tweets are my own and not medical advice
Joined November 2010
- Tweets 216
- Following 867
- Followers 2,104
- Likes 2,508
30 Photos and videos
Joshua Sabari, MD retweeted
Lung cancer updates from @JSabari of @nyulangone @Perlmutter_CC new data #ASCO26 @Aiims1742 @nyugrossman
9
24
2,923
Joshua Sabari, MD retweeted
From emerging therapies to new clinical research, #ASCO2026 brings oncology experts to Chicago, May 29–June 2. Join us for presentations from @nyulangone physicians and researchers.
Check out the full list of our presenters: bit.ly/4fdKFt2
5
14
2,208
Join Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, FCAHS, Pasi A. Jänne, MD, PhD, FASCO, and Joshua Sabari, MD (@JSabari), on 5/30 at 6:30 PM CDT during #ASCO26 for an #NSCLC #MedEd event. Produced with @LUNGevity ➡️ bit.ly/2026EGFRLung-T #Oncology
9
16
201
Joshua Sabari, MD retweeted
May 11
🚨@OncBrothers are moderating the 3rd Annual Upstate Cancer Symposium!
⭐️Full Day CME event bringing the latest in oncology to community practice!
@PTarantinoMD @jainprantesh @rukitamehta @rutikamehtaMD @DrR_DUNNE
#OncTwitter #MedTwitter
Full details: oncupdates.com/article/oncol…
8
11
971
Joshua Sabari, MD retweeted
Apr 16
First line oral targeted therapy for advanced non small cell lung cancer, including responses observed in dreaded brain metastatic disease (thanks to the chemistry behind Zongertinib crossing BBB). New study in @NEJM
nejm.org/doi/full/10.1056/NE…
@JSabari @Perlmutter_CC
2
14
74
5,836
Joshua Sabari, MD retweeted
Feb 20
Permitting NGS results do not identify oncogenic drivers or co-mutations that would favor alternative approaches (i.e., non IO, TKI instead).
1
6
563
25 Oct 2025
You are invited to learn about Lung Cancer Treatment Breakthroughs at @Perlmutter_CC @nyulangone Thursday December 11, 2025 6-7PM EST @StermanDaniel, Benjamin Cooper, Harvey Pass, Abraham Chachoua. i.nyulangone.org/vl6
4
1
6
1,109
9 Aug 2025
FDA approval for lung cancer med Hernexeos fiercepharma.com/pharma/boeh… @Perlmutter_CC @nyulangone @EGFRResisters @Exon20Group
1
2
20
1,322
Joshua Sabari, MD retweeted
8 Aug 2025
Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2 :
- 71% ORR w/ 14.1mos mDoR
- mPFS 12.4%
- ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash
#OncTwitter #MedTwitter
11 Jul 2025
Missed out on AACR 2025? Check out the highlights from Beamion Lung-1! @sawyer_bawek highlights the 🔑 takeaways below!
oncupdates.com/articles/beam…
🔹ORR 71%
🔹mPFS 12.4 months
🔹Intracranial ORR 41%
🔹Improved AE profile
@OncBrothers @AACR #MedTwitter #FOAMed #LungCancer #NSCLC
3
25
59
22,151
Joshua Sabari, MD retweeted
8 Aug 2025
FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD.
fda.gov/drugs/resources-info…
6
36
115
8,673
Joshua Sabari, MD retweeted
8 Aug 2025
#FDA grants accelerated approval to a treatment for non-small cell lung cancer.
fda.gov/drugs/resources-info…
ALT Text: FDA grants accelerated approval for a new treatment for non-small cell lung cancer.
2
5
15
4,211
14 Jul 2025
Honored to be an Expert Judge Mentor for #EGFRSummit! Submit your abstracts by 8/8 to be part of the next class of @EGFRSummit Young Investigators! ➡️ ce.ceconcepts.com/EGFR2025CF…
#EGFR #LCSM #MedTwitter #MedEd
2
13
911
Joshua Sabari, MD retweeted
25 Jun 2025
Discussing data hot off the press here at #HawaiiLung25.
Dr. Joshua Sabari reviews the latest FDA approval of DatoDXd for our patients with EGFR mNSCLC.
1
2
16
2,262
Joshua Sabari, MD retweeted
20 Jun 2025
Advancements Reshape Treatment for Non-Small Cell Lung Cancer @JSabari @Perlmutter_CC @jainprantesh @RoswellPark #LungCancer curetoday.com/view/advanceme…
3
11
818
Joshua Sabari, MD retweeted
15 Jun 2025
📣 HCPs 📣
Do you treat pts w/ rare alterations of #NSCLC?
Medical Oncologist Dr @JSabari and Debra Montague (President of @LungCancerEu/founder of @UKALK1) share views on:
➡️The pt pathway
➡️#MedOnc vs Patient needs
➡️The support currently available
Watch the video/listen on Spotify/Apple: cor2ed.com/lung-connect/prog…
🤝Endorsed by several Patient Advocacy Groups, inc. @WarOnCancer @BrafBombers @Exon20Group @metcrusaders @BiomarkerCo @LungCancerEu & ALK Positive Europe
Supported by an Independent Educational Grant from Boehringer Ingelheim
#MedEd #NSCLC #PrecisionMedicine 📷
1
2
444
Join Joshua Sabari, MD (@JSabari), Jonathan W. Goldman, MD, Gilberto Lopes, MD, MBA, FASCO (@GlopesMd), Zosia Piotrowska, MD, MHS (@ZPiotrowskaMD) & @OncBrothers, on 5/31 at 6:30 PM CDT during #ASCO25 for an #NSCLC #MedEd event. Produced w/ @Lungevity.
bit.ly/25TT-T
1
14
20
1,899
15 May 2025
Getting excited for ASCO 2025! Join us Sat, May 31 at The Sheraton Grand Chicago Riverwalk in Chicago 6 Ballroom for #PrecisionMedicine in #NSCLC at #ASCO25! 6:30 PM CDT Reg & Dinner | 7 PM CDTSymposium. @PeerView @LUNGevity @OncBrothers ➡️ bit.ly/25TT-T
18
25
2,156
5 May 2025
Real World Data on Overall Survival in EGFR mutant NSCLC treated with first line Osimertinib @Perlmutter_CC @nyulangone @JTOonline
jto.org/article/S1556-0864(2…
2
16
60
4,659